Ascorbic acid restores sensitivity to imatinib via suppression of Nrf2-dependent gene expression in the imatinib-resistant cell line

Experimental Hematology

Volumn 32, Issue 4, 2004, Pages 375-381

  Tarumoto, Takahisa ^a   Nagai, Tadashi ^a   Ohmine, Ken ^a   Miyoshi, Takuji ^a   Nakamura, Makiko ^a   Kondo, Takahito ^b   Mitsugi, Kenji ^c   Nakano, Syuji ^c   Muroi, Kazuo ^a   Komatsu, Norio ^a   Ozawa, Keiya ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE; IMATINIB; MESSENGER RNA; PROTEIN SUBUNIT; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; CELL LINE; CELL NUCLEUS; CYTOPLASM; DNA BINDING; DNA RESPONSIVE ELEMENT; DNA SYNTHESIS INHIBITION; DRUG RESISTANCE; ENZYME SYNTHESIS; GENE ACTIVITY; GENE EXPRESSION; GENE REPRESSION; GENE TRANSLOCATION; HUMAN; HUMAN CELL; IC 50; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING;

ANTINEOPLASTIC AGENTS; ASCORBIC ACID; BLAST CRISIS; DNA, NEOPLASM; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, LEUKEMIC; GLUTAMATE-CYSTEINE LIGASE; HUMANS; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; PIPERAZINES; PROTEIN TRANSPORT; PYRIMIDINES; REGULATORY SEQUENCES, NUCLEIC ACID; RNA, NEOPLASM; TRANS-ACTIVATORS;

EID: 12144289484     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2004.01.007     Document Type: Article

References (32)

1. Druker B.J., Talpaz M., Resta D.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 344:2001;1031-1037.
2. Druker B.J., Sawyers C.L., Kantarjian H., et al. Activity of a specific inhibitor of the BCR/ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 344:2001;1038-1042.
3. Sawyers C.L., Hochhaus A., Feldman E., et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 99:2002;3530-3539.
4. le Coutre P., Tassi E., Varella-Garcia M., et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood. 95:2000;1758-1766.
5. Weisberg E., Griffin J.D. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood. 95:2000;3498-3505.
6. + cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood. 96:2000;1070-1079.
7. Gorre M.E., Mohammed M., Ellwood K., et al. Clinical resistance to STI571 cancer therapy caused by BCR-ABL gene mutation of amplification. Science. 293:2001;876-880.
8. + acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood. 99:2002;3472-3475.
9. + leukemic cells to the Abl inhibitor STI571. J Natl Cancer Inst. 92:2000;1641-1650.
10. Venugopal R., Jaiswal A.K. Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. Proc Natl Acad Sci USA. 93:1996;14960-14965.
11. Venugopal R., Jaiswal A.K. Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes. Oncogene. 17:1998;3145-3156.
12. Itoh K., Wakabayashi N., Katoh Y., et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 13:1999;76-86.
13. Itoh K., Chiba T., Takahashi S., et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun. 236:1997;313-322.
14. Ishii T., Itoh K., Takahashi S., et al. Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J Biol Chem. 275:2000;16023-16029.
15. Richman P.G., Meister A. Regulation of γ-glutamyl-cysteine synthetase by nonallosteric feedback inhibition by glutathione. J Biol Chem. 250:1975;1422-1426.
16. Meister A. Glutathione metabolism. Methods Enzymol. 251:1995;3-7.
17. Filomeni G., Rotilio G., Ciriolo M.R. Glutathione disulfide induces apoptosis in U937 cells by a redox-mediated p38 MAP kinase pathway. FASEB J. 17:2003;64-66.
18. Kong A.N., Yu R., Lei W., Mandlekar S., Tan T.H., Ucker D.S. Differential activation of MAPK and ICE/Ced-3 protease in chemical-induced apoptosis: the role of oxidative stress in the regulation of mitogen-activated protein kinases (MAPKs) leading to gene expression and survival or activation of caspases leading to apoptosis. Restor Neurol Neurosci. 12:1998;63-70.
19. Haddad J.J. Redox regulation of pro-inflammatory cytokines and IκB-α/NF-κB nuclear translocation and activation. Biochem Biophys Res Commun. 296:2002;847-856.
20. Hayes J.D., Pulford D.J. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol. 30:1995;445-600.
21. Iida T., Mori E., Mori K., et al. Co-expression of γ- glutamylcysteine synthetase sub-units in response to cisplatin and doxorubicin in human cancer cells. Int J Cancer. 82:1999;405-411.
22. Takemura H., Urasaki Y., Yoshida A., Fukushima T., Ueda T. Simultaneous treatment with 1-β-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells. Cancer Res. 61:2001;172-177.
23. Moinova H.R., Mulcahy R.T. An electrophile responsive element (EpRE)regulates β-naphthoflavone induction of the human γ-glutamylcysteine synthetase regulatory subunit gene. Constitutive expression is mediated by an adjacent AP-1 site. J Biol Chem. 273:1998;14683-14689.
24. Kubonishi I., Miyoshi I. Establishment of a Ph1 chromosome-positive cell line from chronic myelogenous leukemia in blast crisis. Int J Cell Cloning. 1:1983;105-117.
25. Ohmine K., Nagai T., Tarumoto T., et al. Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR. Stem Cells. 21:2003;315-321.
26. Anderson M.E., Levy E.J., Meister A. Preparation and use of glutathione monoesters. Methods Enzymol. 234:1994;492-499.
27. Nagai T., Tarumoto T., Miyoshi T., et al. Oxidative stress is involved in hydroxyurea-induced erythroid differentiation. Br J Haematol. 121:2003;657-661.
28. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 162:1987;156-159.
29. + human leukemia-derived cell lines. Blood. 84:1994;1074-1084.
30. Lassar A.B., Davis R.L., Wright W.E., et al. Functional activity of myogenic HLH proteins requires hetero-oligomerization with E12/E47-like proteins in vivo. Cell. 66:1991;305-315.
31. Nagai T., Harigae H., Furuyama K., et al. 5-aminolevulinate synthase expression and hemoglobin synthesis in a human myelogenous leukemia cell line. J Biochem (Tokyo). 121:1997;487-495.
32. Sattler M., Verma S., Shrikhande G., et al. The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem. 275:2000;24273-24278.